Selected research
Market Structure
Global Oral Anti-Diabetic Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Oral Anti-Diabetic Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Oral Anti-Diabetic Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Oral Anti-Diabetic Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Oral Anti-Diabetic Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Oral Anti-Diabetic Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Oral Anti-Diabetic Drug include Astellas, Biocon, Boehringer Ingelheim, Bristol Myers Squibb, Merck And Co., AstraZeneca, Pfizer, Eli Lilly and Novartis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Oral Anti-Diabetic Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Oral Anti-Diabetic Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Oral Anti-Diabetic Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Oral Anti-Diabetic Drug market size, projected growth trends, production technologies, key applications, and end-use industries.
Oral Anti-Diabetic Drug Segment by Company
Astellas
Biocon
Boehringer Ingelheim
Bristol Myers Squibb
Merck And Co.
AstraZeneca
Pfizer
Eli Lilly
Novartis
Sanofi
Takeda
Abbott
Janssen Pharmaceuticals
Oral Anti-Diabetic Drug Segment by Type
Gliclazide
Glimepiride
Glyburide
Others
Oral Anti-Diabetic Drug Segment by Application
Hospital
Research Institual
Oral Anti-Diabetic Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oral Anti-Diabetic Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Oral Anti-Diabetic Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oral Anti-Diabetic Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Oral Anti-Diabetic Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Oral Anti-Diabetic Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Oral Anti-Diabetic Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Oral Anti-Diabetic Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Gliclazide
- Glimepiride
- Glyburide
- Others
Applications
- Hospital
- Research Institual
Companies covered
- Astellas
- Biocon
- Boehringer Ingelheim
- Bristol Myers Squibb
- Merck And Co.
- AstraZeneca
- Pfizer
- Eli Lilly
- Novartis
- Sanofi
- Takeda
- Abbott
- Janssen Pharmaceuticals
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Oral Anti-Diabetic Drug Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Oral Anti-Diabetic Drug Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Oral Anti-Diabetic Drug Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Oral Anti-Diabetic Drug Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Oral Anti-Diabetic Drug Market Dynamics
- 2.1 Oral Anti-Diabetic Drug Industry Trends
- 2.2 Oral Anti-Diabetic Drug Industry Drivers
- 2.3 Oral Anti-Diabetic Drug Industry Opportunities and Challenges
- 2.4 Oral Anti-Diabetic Drug Industry Restraints
3 Oral Anti-Diabetic Drug Market by Manufacturers
- 3.1 Global Oral Anti-Diabetic Drug Revenue by Manufacturers (2021-2026)
- 3.2 Global Oral Anti-Diabetic Drug Sales by Manufacturers (2021-2026)
- 3.3 Global Oral Anti-Diabetic Drug Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Oral Anti-Diabetic Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Oral Anti-Diabetic Drug Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Oral Anti-Diabetic Drug Manufacturers, Product Type & Application
- 3.7 Global Oral Anti-Diabetic Drug Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Oral Anti-Diabetic Drug Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Oral Anti-Diabetic Drug Players Market Share by Revenue in 2025
- 3.8.3 2025 Oral Anti-Diabetic Drug Tier 1, Tier 2, and Tier 3
4 Oral Anti-Diabetic Drug Market by Type
- 4.1 Oral Anti-Diabetic Drug Type Introduction
- 4.1.1 Gliclazide
- 4.1.2 Glimepiride
- 4.1.3 Glyburide
- 4.1.4 Others
- 4.2 Global Oral Anti-Diabetic Drug Sales by Type
- 4.2.1 Global Oral Anti-Diabetic Drug Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Oral Anti-Diabetic Drug Sales by Type (2021-2032)
- 4.2.3 Global Oral Anti-Diabetic Drug Sales Market Share by Type (2021-2032)
- 4.3 Global Oral Anti-Diabetic Drug Revenue by Type
- 4.3.1 Global Oral Anti-Diabetic Drug Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Oral Anti-Diabetic Drug Revenue by Type (2021-2032)
- 4.3.3 Global Oral Anti-Diabetic Drug Revenue Market Share by Type (2021-2032)
5 Oral Anti-Diabetic Drug Market by Application
- 5.1 Oral Anti-Diabetic Drug Application Introduction
- 5.1.1 Hospital
- 5.1.2 Research Institual
- 5.2 Global Oral Anti-Diabetic Drug Sales by Application
- 5.2.1 Global Oral Anti-Diabetic Drug Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Oral Anti-Diabetic Drug Sales by Application (2021-2032)
- 5.2.3 Global Oral Anti-Diabetic Drug Sales Market Share by Application (2021-2032)
- 5.3 Global Oral Anti-Diabetic Drug Revenue by Application
- 5.3.1 Global Oral Anti-Diabetic Drug Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Oral Anti-Diabetic Drug Revenue by Application (2021-2032)
- 5.3.3 Global Oral Anti-Diabetic Drug Revenue Market Share by Application (2021-2032)
6 Global Oral Anti-Diabetic Drug Sales by Region
- 6.1 Global Oral Anti-Diabetic Drug Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Oral Anti-Diabetic Drug Sales by Region (2021-2032)
- 6.2.1 Global Oral Anti-Diabetic Drug Sales by Region (2021-2026)
- 6.2.2 Global Oral Anti-Diabetic Drug Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Oral Anti-Diabetic Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Oral Anti-Diabetic Drug Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Oral Anti-Diabetic Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Oral Anti-Diabetic Drug Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Oral Anti-Diabetic Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Oral Anti-Diabetic Drug Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Oral Anti-Diabetic Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Oral Anti-Diabetic Drug Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Oral Anti-Diabetic Drug Revenue by Region
- 7.1 Global Oral Anti-Diabetic Drug Revenue by Region
- 7.1.1 Global Oral Anti-Diabetic Drug Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Oral Anti-Diabetic Drug Revenue by Region (2021-2026)
- 7.1.3 Global Oral Anti-Diabetic Drug Revenue by Region (2027-2032)
- 7.1.4 Global Oral Anti-Diabetic Drug Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Oral Anti-Diabetic Drug Revenue (2021-2032)
- 7.2.2 North America Oral Anti-Diabetic Drug Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Oral Anti-Diabetic Drug Revenue (2021-2032)
- 7.3.2 Europe Oral Anti-Diabetic Drug Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Oral Anti-Diabetic Drug Revenue (2021-2032)
- 7.4.2 Asia-Pacific Oral Anti-Diabetic Drug Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Oral Anti-Diabetic Drug Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Oral Anti-Diabetic Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Astellas
- 8.1.1 Astellas Company Information
- 8.1.2 Astellas Business Overview
- 8.1.3 Astellas Oral Anti-Diabetic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Astellas Oral Anti-Diabetic Drug Product Portfolio
- 8.1.5 Astellas Recent Developments
- 8.2 Biocon
- 8.2.1 Biocon Company Information
- 8.2.2 Biocon Business Overview
- 8.2.3 Biocon Oral Anti-Diabetic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Biocon Oral Anti-Diabetic Drug Product Portfolio
- 8.2.5 Biocon Recent Developments
- 8.3 Boehringer Ingelheim
- 8.3.1 Boehringer Ingelheim Company Information
- 8.3.2 Boehringer Ingelheim Business Overview
- 8.3.3 Boehringer Ingelheim Oral Anti-Diabetic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Boehringer Ingelheim Oral Anti-Diabetic Drug Product Portfolio
- 8.3.5 Boehringer Ingelheim Recent Developments
- 8.4 Bristol Myers Squibb
- 8.4.1 Bristol Myers Squibb Company Information
- 8.4.2 Bristol Myers Squibb Business Overview
- 8.4.3 Bristol Myers Squibb Oral Anti-Diabetic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Bristol Myers Squibb Oral Anti-Diabetic Drug Product Portfolio
- 8.4.5 Bristol Myers Squibb Recent Developments
- 8.5 Merck And Co.
- 8.5.1 Merck And Co. Company Information
- 8.5.2 Merck And Co. Business Overview
- 8.5.3 Merck And Co. Oral Anti-Diabetic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Merck And Co. Oral Anti-Diabetic Drug Product Portfolio
- 8.5.5 Merck And Co. Recent Developments
- 8.6 AstraZeneca
- 8.6.1 AstraZeneca Company Information
- 8.6.2 AstraZeneca Business Overview
- 8.6.3 AstraZeneca Oral Anti-Diabetic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 AstraZeneca Oral Anti-Diabetic Drug Product Portfolio
- 8.6.5 AstraZeneca Recent Developments
- 8.7 Pfizer
- 8.7.1 Pfizer Company Information
- 8.7.2 Pfizer Business Overview
- 8.7.3 Pfizer Oral Anti-Diabetic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Pfizer Oral Anti-Diabetic Drug Product Portfolio
- 8.7.5 Pfizer Recent Developments
- 8.8 Eli Lilly
- 8.8.1 Eli Lilly Company Information
- 8.8.2 Eli Lilly Business Overview
- 8.8.3 Eli Lilly Oral Anti-Diabetic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Eli Lilly Oral Anti-Diabetic Drug Product Portfolio
- 8.8.5 Eli Lilly Recent Developments
- 8.9 Novartis
- 8.9.1 Novartis Company Information
- 8.9.2 Novartis Business Overview
- 8.9.3 Novartis Oral Anti-Diabetic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Novartis Oral Anti-Diabetic Drug Product Portfolio
- 8.9.5 Novartis Recent Developments
- 8.10 Sanofi
- 8.10.1 Sanofi Company Information
- 8.10.2 Sanofi Business Overview
- 8.10.3 Sanofi Oral Anti-Diabetic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Sanofi Oral Anti-Diabetic Drug Product Portfolio
- 8.10.5 Sanofi Recent Developments
- 8.11 Takeda
- 8.11.1 Takeda Company Information
- 8.11.2 Takeda Business Overview
- 8.11.3 Takeda Oral Anti-Diabetic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 Takeda Oral Anti-Diabetic Drug Product Portfolio
- 8.11.5 Takeda Recent Developments
- 8.12 Abbott
- 8.12.1 Abbott Company Information
- 8.12.2 Abbott Business Overview
- 8.12.3 Abbott Oral Anti-Diabetic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.12.4 Abbott Oral Anti-Diabetic Drug Product Portfolio
- 8.12.5 Abbott Recent Developments
- 8.13 Janssen Pharmaceuticals
- 8.13.1 Janssen Pharmaceuticals Company Information
- 8.13.2 Janssen Pharmaceuticals Business Overview
- 8.13.3 Janssen Pharmaceuticals Oral Anti-Diabetic Drug Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.13.4 Janssen Pharmaceuticals Oral Anti-Diabetic Drug Product Portfolio
- 8.13.5 Janssen Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Oral Anti-Diabetic Drug Value Chain Analysis
- 9.1.1 Oral Anti-Diabetic Drug Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Oral Anti-Diabetic Drug Production Mode & Process
- 9.2 Oral Anti-Diabetic Drug Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Oral Anti-Diabetic Drug Distributors
- 9.2.3 Oral Anti-Diabetic Drug Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst